Mary Charlotte Y. Carroll

Specialty / Focus. Mary Charlotte Y. Carroll is a trial and appellate litigator whose tracked patent work sits entirely in pharmaceutical/biotech litigation — specifically BPCIA biosimilar disputes over Regeneron's blockbuster eye drug Eylea (aflibercept). Her tracked matter and her broader Law360 case list (12 matters, all Regeneron patent cases) cover patent enforcement against biosimilar manufacturers (Amgen, Celltrion, Sandoz) in the District of New Jersey, C.D. Cal., and the N.D. of West Virginia. Outside patents, her firm bio describes a plaintiffs-side practice spanning antitrust, administrative, and constitutional law.

Side preference. Strictly plaintiff-side: 1 of 1 tracked appearances as lead counsel for the patent holder (Regeneron), with 0 defendant-side appearances. Consistent with her Kellogg Hansen background, her patent work is enforcement of an innovator's patents rather than defense or NPE monetization.

Firm context. She began her career as an associate at Kellogg, Hansen, Todd, Figel & Frederick, where her patent work (including the tracked Sandoz matter and related Regeneron cases) has occurred. A Sanford Heisler Sharp McKnight bio lists her as an associate there following a Fifth Circuit clerkship with Judge Gregg Costa, though her 2024–2025 patent matters are docketed under Kellogg Hansen; current affiliation should be confirmed. She is not in-house.

Notable cases / outcomes. Her tracked matter, Regeneron Pharmaceuticals, Inc. v. Sandoz Inc., settled in September 2025, allowing Sandoz's Eylea biosimilar Enzeevu to launch in the U.S. in Q4 2026 (or earlier under certain conditions). She was also listed among Regeneron's counsel in related litigation against Amgen and Celltrion; the Celltrion matter settled in October 2025. The IP Fray report confirms her as part of the Kellogg Hansen team in the Sandoz case, alongside Williams & Connolly and Paul Weiss.

PTAB / IPR experience. No appearances in IPR/PGR proceedings were found in web-available sources; her track record is district-court BPCIA litigation.

Bar / education. J.D., Yale Law School; M.Phil., University of Cambridge; B.A., Rice University (summa cum laude). Admitted Texas (2021) and D.C. (2022).